𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Cost of care for early- and late-stage oral and pharyngeal cancer in the California Medicaid population

✍ Scribed by Joshua D. Epstein; Tara K. Knight; Joel B. Epstein; Mark A. Bride; Michael B. Nichol


Publisher
John Wiley and Sons
Year
2008
Tongue
English
Weight
194 KB
Volume
30
Category
Article
ISSN
1043-3074

No coin nor oath required. For personal study only.

✦ Synopsis


Abstract

Background.

This study documents the direct medical costs associated with treating oral and pharyngeal squamous cell carcinoma (OSCC) as early‐ or late‐stage disease according to the current standard of care.

Methods.

This retrospective analysis of California Medicaid claims data calculated direct payments for patients diagnosed with OSCC. Patients were defined as being treated for early‐ or late‐stage disease based on treatment modality. Regression determined significant predictors of year‐1 cost of care following diagnosis.

Results.

Median year‐1 cost of care following initial diagnosis was $25,319 for the 229 patients identified. Regression results determined that treatment modality and medical comorbidities were significant in predicting costs (p < .05). Costs for patients treated as having early‐stage OSCC were approximately 36% less than for those treated as having late‐stage disease (p = .002).

Conclusion.

Treatment for OSCC is a significant cost from Medicaid's perspective, and these data suggest early detection may ease its economic burden. © 2007 Wiley Periodicals, Inc. Head Neck, 2008


📜 SIMILAR VOLUMES


Cost savings in mass population screenin
✍ David K. Whynes; Andrew R. Walker; Jack D. Hardcastle 📂 Article 📅 1992 🏛 John Wiley and Sons 🌐 English ⚖ 657 KB

The widely-accepted hypothesis of a development sequence from colorectal adenoma to carcinoma is felt by clinicians to legitimate adenoma excision during routine colonoscopic investigation. Using published data on adenoma development, and adenoma prevalence data derived from the Nottingham colorecta

Prognostic factors for survival of stage
✍ S.-H. Ignatius Ou; Jason A. Zell; Argyrios Ziogas; Hoda Anton-Culver 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 180 KB 👁 2 views

## Abstract ## BACKGROUND. Platinum‐based adjuvant chemotherapy in randomized trials has failed to provide a survival benefit in patients with resected stage I nonsmall cell lung cancer (NSCLC). Using data from the California Cancer Registry (CCR), we explored factors that had detrimental effects